Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.53 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.53 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13627154 | 0.98 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL11936429 | 0.89 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL29843924 | 0.80 | ALDH1A1 (0.39) | SMN1; SMN2NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL8165938 | 0.79 | NPC1 (1.00) | SMN1; SMN2NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL2377367 | 0.79 | NPC1 (1.00) | SMN1; SMN2NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL23736058 | 0.79 | NPC1 (1.00) | SMN1; SMN2NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL3076504 | 0.79 | NPC1 (1.00) | SMN1; SMN2NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL931108 | 0.78 | NPSR1 (0.62) | SMN1; SMN2NPC1RAB9AMAPTEPHX1 | |
| SCHEMBL931220 | 0.78 | NPSR1 (0.62) | SMN1; SMN2NPC1RAB9AMAPTEPHX1 | |
| SCHEMBL19669665 | 0.78 | NPSR1 (0.62) | SMN1; SMN2NPC1RAB9AMAPTEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-06-22 | — | — | US | disclosed |
| CN-109096139-B | Preparation method of alpha-carbonyl amide derivative | 贵州大学 | 2021-03-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | SMN1; SMN2 3879/4885NPC1 545/4885RAB9A 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.